The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Safety and anti-tumor activity of BAY 2927088 in patients with HER2-mutant NSCLC
Nicolas Girard, MD, PhD, Institut Curie, Paris, France, shares findings from a trial on BAY 2927088, a tyrosine kinase inhibitor, for HER2-mutant NSCLC. Among 34 patients treated, a majority showed objective responses and a promising median progression-free survival was also reported. BAY 2927088 demonstrated a favorable safety profile, with common adverse events being mild diarrhea and rash. The study supports further development of BAY 2927088 in patients with HER2-mutant NSCLC. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Employment – AstraZeneca (I)
Consulting or Advisory Role – Abbvie; AMGEN; AstraZeneca; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Ipsen; Janssen; LEO Pharma; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
Research Funding – AstraZeneca (Inst); BMS (Inst); MSDavenir (Inst); Roche (Inst)
Travel, Accommodations, Expenses – Janssen Oncology; Janssen Oncology; Roche
